Relevance of ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?"
- Use case
- Select a plasma ctDNA fragmentomics detection workflow
- Assessed by
- CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- Relevance
- Proxy evidence
- Endpoint
- Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants
Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc.
9 reviewed evaluations
- allelic imbalance on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- clinical data on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- fragment endpoints on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- fragment lengths on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SCNA on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SCNA-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SNV on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SNV-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- WG methylation on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
20 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Comparison group jamshidi2022-ccga1-detection Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Comparison title CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Constraints3 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Endpoint Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Claimed field links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Headline metric sensitivity-at-98-percent-specificity Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Limitations9 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Pinned records21 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Rationale Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc. The CCGA samples are not public and none of the cohorts behind this use case's existing judgements comes from CCGA, so the samples do not overlap. Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Evaluation of cell-free DNA approaches for multi-cancer early detection · Original source · Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Technical metadata and extraction receipts
Stable ID: use-case-mapping-ctdna-jamshidi-20261010-frag-training-cv
- field
- links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
- value
- ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
- relevance
- proxy
- endpoint
- Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation for the fragment endpoint, fragment length and allelic imbalance classifiers from 30x cfDNA WGS, alongside copy-number, mutation, whole-genome methylation and clinical classifiers on the same participants
- rationale
- Compares two fragmentomic classifiers with other cfDNA features on the same blood draws at a fixed false-positive rate. Proxy evidence: no tumour-fraction-stratified sensitivity is printed, the fragment classifiers were developed after unblinding, and the 98% threshold is post hoc. The CCGA samples are not public and none of the cohorts behind this use case's existing judgements comes from CCGA, so the samples do not overlap.
- constraints
- Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.; The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
- limitations
- Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.; The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.; Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.; Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.; The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.; Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.; Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.; No sensitivity within tumour-fraction strata is printed; per-classifier clinical limits of detection by cTAF are in figures only.; The fragment endpoint, fragment length and allelic imbalance classifiers were developed after validation blinding was lifted, so their validation values are not a blinded validation, even though the source calls the cohort held-out; the copy-number, mutation, methylation and clinical rows were analysed double-blinded.
- citation locators
- source id: ctdnajam-20261010-source-jamshidi2022; locator: Table 3, training columns; STAR Methods
- source locator
- ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods
- revision
- 1
- reason
- Add the CCGA substudy 1 same-sample comparison of cfDNA classifiers (Jamshidi et al. 2022), retrieved 2026-10-10.
- comparison group
- jamshidi2022-ccga1-detection
- comparison title
- CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
- headline metric
- sensitivity-at-98-percent-specificity
- stratum label
- Training set, 10-fold cross-validation
- stratum order
- 1
- reviewed evaluations
- ctdnajam-20261010-eval-training-allelic-imbalance; ctdnajam-20261010-eval-training-clinical-data; ctdnajam-20261010-eval-training-fragment-endpoints; ctdnajam-20261010-eval-training-fragment-lengths; ctdnajam-20261010-eval-training-scna; ctdnajam-20261010-eval-training-scna-wbc; ctdnajam-20261010-eval-training-snv; ctdnajam-20261010-eval-training-snv-wbc; ctdnajam-20261010-eval-training-wg-methylation
- review
- method: automated-source-review; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; reviewed at: 2026-10-10T09:00:00Z; note: Independent review of endpoint fit, relevance grade, limitations, exclusions and grouping against the use case and the article; every value of the listed evaluations was checked against Table 3 or the Results text, with percentages and Clopper-Pearson intervals recomputed. Developer study; no execution, reproduction, human scientific review or clinical validation.
- pins
- record id: ctdnajam-20261010-eval-training-allelic-imbalance; fields: status; links; attributes.origin; attributes.comparison; sha256: d5dbae67229e48fd4758f574fda0db70d7ea0a0455d8d1105ee2c1fee4ba51ba; record id: ctdnajam-20261010-eval-training-clinical-data; fields: status; links; attributes.origin; attributes.comparison; sha256: 1d52b51d39fa7581e10f3a7fc9011a7d0d58bbe4a0d40d22e728eeccb33136fb; record id: ctdnajam-20261010-eval-training-fragment-endpoints; fields: status; links; attributes.origin; attributes.comparison; sha256: 3f6113038c4b589e58f6e01632f8296bed18a8e30d12e6c1ef26e442e7b651d5; record id: ctdnajam-20261010-eval-training-fragment-lengths; fields: status; links; attributes.origin; attributes.comparison; sha256: 8baa47c31c3be9c7d563d758f452c12c125b42bce1f0f5eef59ed922c70fcb14; record id: ctdnajam-20261010-eval-training-scna; fields: status; links; attributes.origin; attributes.comparison; sha256: 308b3a9f74982fbe8704819025d5434558cf07ab23b8b80e2c06d7ea9e36b864; record id: ctdnajam-20261010-eval-training-scna-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: d60a82250add685a70cec0035e890ff8cca597a2f18ee755711cda02d740da51; record id: ctdnajam-20261010-eval-training-snv; fields: status; links; attributes.origin; attributes.comparison; sha256: b192bf6cb8b40bfd6a9bac2d7e8e46dc3b8260dc3ba58443d7f4d4db21c5c9cc; record id: ctdnajam-20261010-eval-training-snv-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: 9eeb50a8399c1e7382a39110181b54c03a30f28899434225f6090baf61fd98ad; record id: ctdnajam-20261010-eval-training-wg-methylation; fields: status; links; attributes.origin; attributes.comparison; sha256: ee219db71a2d985de4b230b91d409083aa64e21e996808f8df1bf3297e6562a9; record id: ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec; fields: status; name; description; facets; source_ids; links; attributes; sha256: 989df2f01c0e0680982046687453cf8e01eaff06fdd2cef30b77956a4c047935; record id: ctdnajam-20261010-result-training-allelic-imbalance-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: fe3448280770c20f1b54af865af886913eb02846288fc626da8bf6ca045a369b; record id: ctdnajam-20261010-result-training-clinical-data-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9aa5ea94d9bc7d5a2d13ca1fb78c40c6eb3ec8d957f7c10d44ef389c0dc3b25f; record id: ctdnajam-20261010-result-training-fragment-endpoints-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: ffaa2d34ae152a077662dfdc8a9a0227dc236e856e7e6a983161aada80e04025; record id: ctdnajam-20261010-result-training-fragment-lengths-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: f293f78f2dd57171218e475f5bb303b5da6516110e1735a9984467d04b3c582b; record id: ctdnajam-20261010-result-training-scna-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 55800b64e75e349c9574302a38d6f4e067437e0161e3e02c76d784e3bfc486a0; record id: ctdnajam-20261010-result-training-scna-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 473993745009b5df1d857d423f4dcb9e5c66f3f43e99ce6fb4397d3c6a81bebd; record id: ctdnajam-20261010-result-training-snv-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9c699789969b9519eb9134425fbb111acd7b94729d7dd9e2f08ab2d306436716; record id: ctdnajam-20261010-result-training-snv-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 311545249c9bd2489f49e6fb53bf049a45a90e4987054e8f1088bb2cf8f7151e; record id: ctdnajam-20261010-result-training-wg-methylation-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 3d870e6f22ac02c7ff9605e5bd212bbd87657fc2e225ec789da75e4b2ddd3f40; record id: ctdnajam-20261010-source-jamshidi2022; fields: status; attributes.artifact_sha256; sha256: 49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08